Innovative Partnership to Advance Next-Generation Influenza Vaccines in Europe SK bioscience, IDT Biologika, and Vaxxas join forces to develop next-generation influenza vaccines, aiming to enhance public health resilience and accessibility.

Innovative Partnership to Advance Next-Generation Influenza Vaccines in Europe #South_Korea #Incheon #SK_bioscience #IDT_Biologika #Vaxxas

ObvioHealth and Vaxxas Forge Strategic Partnership for Innovative Needle-Free Vaccination Trials ObvioHealth joins forces with Vaxxas in a groundbreaking agreement to enhance needle-free vaccination technologies using ObvioGo® for clinical trials.

ObvioHealth and Vaxxas Forge Strategic Partnership for Innovative Needle-Free Vaccination Trials #United_States #New_York #ObvioHealth #Vaxxas #HD-MAP

Funding Raises: #Upstart $600M Post-IPO Debt; #Cognition $500M Series C; #Cohere $500M Series D; #MassCompute $300M PE Round; #Wugen $115M Series C; #LivePerson $115M Post-IPO Debt; #Framer $100M Series D; #ProVerum $80M Series B; #Vaxxas A$90M Series D; #Rain $58M Series B